Rivosana - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 14,352 | 175,016 | 293,923 | 683,690 | 776,968 | 1,752,756 | 453,551 | 1,003,707 |
| Profit before tax | -158 | -172 | 49,740 | 122,550 | -2,101 | 268,672 | -49,176 | 290,052 |
| Net profit | -183 | -286 | 47,276 | 104,166 | -2,982 | 228,489 | -49,176 | 255,124 |
| Equity | 2,317 | 2,032 | 49,308 | 153,473 | 122,447 | 220,936 | 133,761 | 388,885 |
| Liabilities | 2,063 | 10,609 | 0 | 82,999 | 298,146 | 108,518 | 88,752 | 164,421 |
| Non-current assets | 0 | 0 | 0 | 28,335 | 23,825 | 46,315 | 37,277 | 67,865 |
| Current assets | 4,380 | 12,641 | 288,498 | 208,137 | 396,436 | 281,424 | 182,978 | 489,062 |
| Total assets | 4,380 | 12,641 | 288,498 | 236,472 | 420,261 | 327,739 | 220,255 | 556,927 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 148,169 | 126,729 | 170,382 |
| Social insurance contributions | - | - | - | - | - | 38,876 | 41,097 | 40,174 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | +1119.5% | +67.9% | +132.6% | +13.6% | +125.6% | -74.1% | +121.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -4.2% | -2.3% | 16.4% | 44.1% | -0.7% | 69.7% | -22.3% | 45.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -7.9% | -14.1% | 95.9% | 67.9% | -2.4% | 103.4% | -36.8% | 65.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -1.3% | -0.2% | 16.1% | 15.2% | -0.4% | 13.0% | -10.8% | 25.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -1.1% | -0.1% | 16.9% | 17.9% | -0.3% | 15.3% | -10.8% | 28.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.9 | 5.2 | - | 0.5 | 2.4 | 0.5 | 0.7 | 0.4 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 9,568 | 175,016 | 293,923 | 170,923 | 116,545 | 300,474 | 59,159 | 108,509 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Rivosana - Social security debts
The company had no debts to Sodra
Rivosana - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-12-31 | 2025-12-31 | 2367.75 |
| 2025-09-01 | 2025-09-01 | 10097.06 |
| 2025-08-28 | 2025-08-31 | 10081.34 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Rivosana, UAB (code 304559755) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €1.00M and net profit of €255.1K, with a profit margin of 25.4%. This was a strong rebound from 2024, when revenue fell to €453.6K and the company posted a net loss of €49.2K, after a much stronger 2023 result of €1.75M in revenue and €228.5K in net profit. The three-year pattern shows a sharp contraction in 2024 followed by renewed growth and profitability in 2025. At the end of 2025, total assets stood at €556.9K, equity at €388.9K and liabilities at €164.4K, indicating a solid capital base. Key ratios also point to efficient use of resources, with return on equity at 65.6%, return on assets at 45.8%, debt-to-equity at 0.42 and asset turnover at 1.80x. Revenue per employee was €111.5K, while profit per employee reached €28.3K.